|
Status |
Public on Jul 13, 2017 |
Title |
Click chemistry enables comprehensive preclinical evaluation of targeted epigenetic therapies |
Organism |
Homo sapiens |
Experiment type |
Genome binding/occupancy profiling by high throughput sequencing Expression profiling by high throughput sequencing
|
Summary |
This SuperSeries is composed of the SubSeries listed below.
|
|
|
Overall design |
Refer to individual Series
|
|
|
Citation(s) |
28619718 |
|
Submission date |
Oct 14, 2016 |
Last update date |
May 15, 2019 |
Contact name |
Mark Dawson |
E-mail(s) |
mark.dawson@petermac.org
|
Organization name |
Peter MacCallum Cancer Centre
|
Street address |
305 Grattan Street
|
City |
Melbourne |
State/province |
VIC |
ZIP/Postal code |
3000 |
Country |
Australia |
|
|
Platforms (2) |
GPL11154 |
Illumina HiSeq 2000 (Homo sapiens) |
GPL18573 |
Illumina NextSeq 500 (Homo sapiens) |
|
Samples (36)
|
|
This SuperSeries is composed of the following SubSeries:
|
GSE88746 |
Click chemistry enables comprehensive preclinical evaluation of targeted epigenetic therapies [ChIP-seq 1] |
GSE88747 |
Click chemistry enables comprehensive preclinical evaluation of targeted epigenetic therapies [ChIP-seq 2] |
GSE88748 |
Click chemistry enables comprehensive preclinical evaluation of targeted epigenetic therapies [Click-Seq 1] |
GSE88749 |
Click chemistry enables comprehensive preclinical evaluation of targeted epigenetic therapies [Click-Seq 2] |
GSE88750 |
Click chemistry enables comprehensive preclinical evaluation of targeted epigenetic therapies [RNA-seq] |
|
Relations |
BioProject |
PRJNA348447 |